Skip to search
Skip to main content
Back to Search
Start Over
Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
Authors :
Huber, Henriette Tausch, Eugen Schneider, Christof Edenhofer, Simone Von Tresckow, Julia Robrecht, Sandra Giza, Adam Zhang, Can Furstenau, Moritz Dreger, Peter Ritgen, Matthias Illmer, Thomas Illert, Anna Lena Duerig, Jan Boettcher, Sebastian Niemann, Carsten Utoft Kneba, Michael Fink, Anna-Maria Fischer, Kirsten Doehner, Hartmut Hallek, Michael Eichhorst, Barbara Stilgenbauer, Stephan Huber, Henriette Tausch, Eugen Schneider, Christof Edenhofer, Simone Von Tresckow, Julia Robrecht, Sandra Giza, Adam Zhang, Can Furstenau, Moritz Dreger, Peter Ritgen, Matthias Illmer, Thomas Illert, Anna Lena Duerig, Jan Boettcher, Sebastian Niemann, Carsten Utoft Kneba, Michael Fink, Anna-Maria Fischer, Kirsten Doehner, Hartmut Hallek, Michael Eichhorst, Barbara Stilgenbauer, Stephan
Publication Year :
2022
Details
Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1383745202
Document Type :
Electronic Resource